ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis €41.40 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChart About Biotest Aktiengesellschaft Stock (ETR:BIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIO alerts:Sign Up Key Stats Today's Range€41.40▼€41.4050-Day Range€41.40▼€42.4052-Week Range€40.40▼€43.40VolumeN/AAverage Volume1,927 shsMarket Capitalization$819.31 millionP/E Ratio9.98Dividend Yield0.10%Price TargetN/AConsensus RatingN/A Company OverviewBiotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address BIO Stock News HeadlinesEQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchangedNovember 15, 2024 | markets.businessinsider.comBiotest Aktiengesellschaft (BIESF)August 30, 2024 | au.finance.yahoo.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 21, 2024 | Crypto Swap Profits (Ad)Biotest Aktiengesellschaft (BIO3.F)August 13, 2024 | nz.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.SW)August 4, 2024 | ca.finance.yahoo.comBiotest Aktiengesellschaft (BIO3D.XC)August 4, 2024 | ca.finance.yahoo.comBiotest baut aus, während Grifols weiter mit Gotham-Schatten kämpft. Ist die Mutter die spannendere Aktie?April 19, 2024 | finanznachrichten.deBiotest Aktiengesellschaft (BIOD.XC)March 10, 2024 | finance.yahoo.comSee More Headlines BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed this year? Biotest Aktiengesellschaft's stock was trading at €42.60 at the beginning of the year. Since then, BIO shares have decreased by 2.8% and is now trading at €41.40. View the best growth stocks for 2024 here. What other stocks do shareholders of Biotest Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryMeasuring And Control Equipment Current SymbolETR:BIO CUSIPN/A CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees8,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€4.15 Trailing P/E Ratio9.98 Forward P/E Ratio345.00 P/E GrowthN/ANet Income$164.40 million Net Margins21.04% Pretax MarginN/A Return on Equity36.16% Return on Assets8.47% Debt Debt-to-Equity Ratio116.50 Current Ratio2.45 Quick Ratio1.66 Sales & Book Value Annual Sales$781.30 million Price / Sales1.05 Cash Flow€1.33 per share Price / Cash Flow31.04 Book Value€13.26 per share Price / Book3.12Miscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap$819.31 million OptionableNot Optionable Beta0.24 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (ETR:BIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotest Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.